Beyond ABVD: Targeted agents and strategies in first line treatment of elderly Hodgkin Lymphoma patients

shutterstock_1065890579 - Image for home page

Modern therapy with targeted agents which improve outcomes in elderly Hodgkin Lymphoma (HL) patients is presented and illustrated with two South African cases

Learning objectives

  • This presentation of classic Hodgkin Lymphoma (HL) discusses the treatment of elderly patients (over the 60 years) and the selection of appropriate therapy
  • It stresses the bimodal incidence of HL in younger patients (20-34 years) as well as elderly patients, with a significant peak in patients aged 75 years and above
  • Two South African cases are presented of patients who at an elderly age are fit and economically active and how targeted agents and strategies resulted in improved Progression Free Survival (PFS) with inclusion of targeted agents in the treatment regimen.
ATTENTIONThis CPD-accredited activity consists of three video presentations and a questionnaire, presented by clinical haematologists Dr Jaimendra P Singh, Dr Anna Sureda and Dr Simon Brett at the Haematology Oncology Conference held on 19 September 2025.Please watch the three videos before attempting to answer the questionnaire.

To access this module, please register or login: